Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia

This study tests a special type of immune cell therapy (called DC-AML cells — dendritic cell vaccines made from your own cells) for people with a blood cancer called Acute Myeloid Leukemia (AML) who are in remission but still have small signs of cancer remaining (called measurable residual disease or MRD). **You may be eligible if...** - You have been diagnosed with AML and have completed chemotherapy and achieved remission - You still have trace amounts of cancer detectable in your bone marrow (MRD positive) - You are not eligible for a stem cell transplant, OR you have had a relapse at the molecular level after transplant **You may NOT be eligible if...** - You do not have AML or have not completed standard induction and consolidation chemotherapy - You do not have detectable residual disease - You have significant other health conditions that would make this treatment unsafe Talk to your doctor to see if this trial is right for you.